Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3108743 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo - Healthy | PLACEBO_COMPARATOR | Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods. |
| LY3108743 - Healthy | EXPERIMENTAL | Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods. |
| Placebo - Diabetes | PLACEBO_COMPARATOR | Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods. |
| LY3108743 - Diabetes | EXPERIMENTAL | Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods. |
| Placebo - Solution | PLACEBO_COMPARATOR | Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods. |
| LY3108743 - Solution | EXPERIMENTAL | Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods. |
| Name | Type | Description |
|---|---|---|
| Placebo - Capsule | DRUG | Administered orally |
| LY3108743 - Capsule | DRUG | Administered orally |
| Placebo - Solution | DRUG | Administered orally |
| LY3108743 - Solution | DRUG | Administered orally |
Inclusion Criteria: * Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes * Have a body mass index (BMI) of 18.5 to 40.0 kilogram per square meter (kg/m\^2), inclusive, at screening * Have normal blood pressure * Participants w...
LY3108743 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated for its safety, tolerability, and pharmacokinetics in clinical trials.
LY3108743 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the drug's potential in treating Type 2 Diabetes Mellitus.
LY3108743 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research for Type 2 Diabetes Mellitus.
LY3108743 has one completed Phase 1 clinical trial, identified as NCT01995656. This study, titled 'A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes,' enrolled 44 participants in Singapore. The trial was randomized, double-blind, and placebo-controlled, and included healthy volunteers.
LY3108743 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Type 2 Diabetes Mellitus. The drug has not completed the clinical trial process required for regulatory approval, and its safety and efficacy have not been established.